Miglustat Capsules

Miglustat capsules are glucosylceramide synthase inhibitors. In 2006, the product was designated as an orphan drug for the treatment of Niemann-Pick disease type C by the European Medicines Agency. In 2009, it was approved for the treatment of progressive neurological symptoms in adult and adolescent patients with Niemann-Pick disease type C. The product has been approved for the treatment of Niemann-Pick disease type C in more than 30 countries including Australia, Canada, Switzerland, and Japan. The product is a drug approved worldwide for the treatment of Niemann-Pick disease type C. The product is 100 mg in size and the dosage is 200 mg orally, three times a day. [1]